Interfere function of panaxoside Rg1 for self immunity myeloencephalitis mouse

An autoimmune and ginsenoside technology, applied in the direction of medical preparations containing active ingredients, allergic diseases, organic active ingredients, etc., to achieve the effect of reducing the incidence of disease

Inactive Publication Date: 2008-08-20
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are rare reports at home and abroad on the experimental research and clinical application research of using Rg1 to intervene in MS.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interfere function of panaxoside Rg1 for self immunity myeloencephalitis mouse
  • Interfere function of panaxoside Rg1 for self immunity myeloencephalitis mouse
  • Interfere function of panaxoside Rg1 for self immunity myeloencephalitis mouse

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Establishment of conditions for ginsenoside Rg1 to intervene in mice with autoimmune encephalomyelitis:

[0029] 1. C57B1 / 6 mice aged 10-12 weeks were induced by immunization with MOG35-55 (300 μg / mouse), and the EAE model was established.

[0030] 2. From the day of induction, the EAE model mice were intervened with ginsenoside Rg1 (10 mg / Kg / day).

[0031] 3. According to the clinical grading table, observe the clinical phenotype of the mice in the normal saline control group and the Rg1 intervention group.

[0032] 4. At the peak of EAE incidence, the brain tissue, neck swelling and waist swelling of the mice in the normal saline control group and the Rg1 intervention group were collected for histopathological analysis.

[0033] The preparation method of ginsenoside Rg1 intervening EAE of the present embodiment:

[0034] 1. Materials: artificially synthesized MOG35-55 (sequence is MEVGWYRSPFSRVVHLYRNGK) peptide chain fragment, incomplete Freund's adjuvant...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an intervention effect of a ginsenoside Rg1 on autoimmune encephalomyelitis mouse, belonging to the field of Chinese herbal medicine monomer intervening disease. The autoimmune encephalomyelitis (EAE) model of cord sheath oligodendrocyte glycoprotein peptide MOG35-55 immune C57BL / 6 mouse is an international accepted multiple sclerosis mouse animal model, establishing the model, and simultaneously inducing, using the ginsenoside Rg1 to intervene, through observing the impact of the ginsenoside Rg1 on the phenotype and the histopathology of the EAE model, obtaining that the ginsenoside Rg1 can significantly reduce the incidence of the autoimmune encephalomyelitis. Therefore, the ginsenoside Rg1 has a certain role in the intervention of multiple sclerosis. The ginsenoside Rg1 can significantly reduce the disease incidence of the multiple sclerosis animal model-EAE mice.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine monomer intervening diseases, specifically applying ginsenoside Rg1 to intervene autoimmune encephalomyelitis mice, and exploring the intervening effect of ginsenoside Rg1 on neuroimmune mechanism of multiple sclerosis. Background technique [0002] Multiple sclerosis (Multiple Sclerosis, MS) is one of the most common neuroimmune diseases, and its incidence can be as high as 3‰ in temperate regions. Young people are prone to the disease, and the age of onset is about 28 years old; it has the characteristics of persistence, recurrence and gradual deterioration. 50% of patients need to walk with crutches 15 years after the first onset, and the disability rate is high. Therefore, this disease is extremely harmful. Since the pathogenesis of MS is still unclear, there is no effective treatment. [0003] The treatment of MS mainly includes symptomatic treatment in the acute attack phase and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K49/00G01N33/48A61K31/704A61P37/02A61P25/00
Inventor 吴志英王柠
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap